title: Innovative therapeutics for inflammatory bowel disease.
abstract: Inflammatory bowel diseases (IBD) are chronic inflammatory conditions of the gastrointestinal tract, which clinically present as one of two disorders, Crohn's disease or ulcerative colitis. Mainstays of drug treatments for IBD include aminosalicylates, corticosteroids and immunosuppressants such as azathioprine, methotrexate and cyclosporin. Advances in basic research of the pathophysiological process in IBD have been applied to generate a variety of new therapeutics targeting at different levels of the inflammatory processes. New therapies are classified as: (1) Anti-TNFalpha antibodies; (2) Recombinant cytokines; (3) Selective adhesion blockade; (4) Growth factors; (5) Innate immunostimulation; (6) Nucleic acid based therapies; (7) Gene therapy; (8) Autologous bone-marrow transplantation; (9) Helminths and (10) Extracorporeal immunomodulation. All treatments have the potential to provide more effective and safe treatment for IBD.
authors.affiliation: Department of Gastroenterology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. Vasco de Quiroga 15, Col. Seccion XVI, Tlalpan, Mexico CP 14000, DF Mexico. kazuofurusho@hotmail.com
authors.forename: Jesus-K
authors.initials: JK
authors.lastname: Yamamoto-Furusho
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000276:immunology / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D016207:Cytokines / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000628:therapy*; D036341:Intercellular Signaling Peptides and Proteins / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D000888:Antibodies, Anti-Idiotypic; D016207:Cytokines; D036341:Intercellular Signaling Peptides and Proteins; D014409:Tumor Necrosis Factor-alpha